Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q1 2023 vs. Q4 2022
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 25 | 27 | +2 |
| Shares | 3.93M | 3.96M | +32.2K (+0.8%) |
| Value | $39.6M | $40.6M | +$1.08M (+2.7%) |
New holders (4)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Glazer Capital, LLC | 374,900 | $3.85M | 0.21% |
| Deutsche Bank AG | 139,494 | $1.43M | 0.00% |
| Caas Capital Management LP | 19,600 | $201.3K | 0.07% |
| Rpo LLC | 13,606 | $139.7K | 0.04% |
Sold out (2)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Vivaldi Asset Management, LLC | 400,000 | $4.07M |
| Citadel Advisors LLC | 93,854 | $954.5K |